COMPLETED

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

Talk to us

Conditions

Macular Degeneration, Age RelatedGeographic Atrophy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy. The main question to answer is which imaging device provides measurements that are most similar to the standard of care device. Participants will be patients of a retina doctor at University Station Eye Clinic with geographic atrophy, and can expect to be in the study for 60-75 minutes.

Official Title

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy (COCO-GA) Protocol

Quick Facts

Study Start:2023-10-06
Study Completion:2025-05-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05961332

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 50 years or older and may be either male or female and may be of any race
  2. * Established diagnosis of GA due to AMD
  3. * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm² to 17.5 mm². GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
  4. * Willing to participate as evidenced by signing the written informed consent
  1. * Unable to tolerate opthalmic imaging
  2. * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
  3. * Presence of significant media opacity preventing adequate retinal imaging
  4. * Presence of concurrent retinal disease which may confound assessment

Contacts and Locations

Principal Investigator

Amitha Domalpally, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

University of Wisconsin
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Amitha Domalpally, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-06
Study Completion Date2025-05-27

Study Record Updates

Study Start Date2023-10-06
Study Completion Date2025-05-27

Terms related to this study

Additional Relevant MeSH Terms

  • Macular Degeneration, Age Related
  • Geographic Atrophy